Three mutations in salmon calcitonin fragment sCT(22-32) increased calcitonin receptor binding 21-fold while retaining high affinity for all three amylin receptor subtypes — a potential lead for dual osteoporosis/diabetes therapy.
21x stronger bindingJust three amino acid changes boosted calcitonin receptor binding 21-fold while maintaining affinity for all three amylin receptor subtypes — a dual-targeting short peptide lead
What the researchers found
Three mutations (N26D, S29P, P32HYP) in sCT(22-32) increased CTR ECD affinity 21-fold. The mutated fragment also retained high affinity for all 3 AMY receptor ECD types (CTR:RAMP1, CTR:RAMP2, CTR:RAMP3).
Why it matters
Osteoporosis and diabetes often co-occur in aging. A single peptide fragment that engages both calcitonin (bone) and amylin (metabolic) receptors could simplify treatment for elderly patients with both conditions.
The numbers in context
21-fold affinity increase; mutations N26D, S29P, P32HYP; retained binding to AMY1, AMY2, AMY3 receptor ECDs
How the study worked
Peptide biochemistry study. Purified CTR and AMY receptor extracellular domains (ECDs). Fluorescence polarization/anisotropy peptide binding assays. Systematic mutation screening of sCT(22-32) fragment.
Who was studied
Purified CTR and AMY receptor extracellular domains
What this study cannot tell us
In vitro binding study using isolated receptor domains — full receptor activation and in vivo efficacy not tested. Short fragment may not fully activate receptors. Pharmacokinetics of the 11-mer peptide unknown. Clinical translation requires substantial development.
How to read the evidence
Low evidence grade: in vitro receptor binding study with isolated ECDs. Functional activation and in vivo effects not demonstrated.
When this study was published
Published 2021. Next-generation calcitonin and amylin receptor drugs continue in development.
The bigger picture
Calcitonin and amylin share receptor components, and this study exploits that relationship to design a multi-target peptide. The approach of engineering short receptor-binding fragments could be applied to other GPCR families for multi-indication drugs.
Questions still open
- Does the mutated sCT(22-32) fragment activate CTR and AMY receptors functionally, not just bind?
- Could this fragment be lipidated or PEGylated for extended half-life?
- Would dual CTR/AMY activation provide synergistic benefits for metabolic bone disease?
Common questions
Why target both calcitonin and amylin receptors?
How can just 3 mutations improve binding 21-fold?
Read the original research
Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors.
Biomolecules, 11(9)
Citation
Lee, Sangmin. (2021). Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors.. Biomolecules, 11(9). https://doi.org/10.3390/biom11091364